RS20050002A - Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method - Google Patents
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and methodInfo
- Publication number
- RS20050002A RS20050002A YUP-2005/0002A YUP20050002A RS20050002A RS 20050002 A RS20050002 A RS 20050002A YU P20050002 A YUP20050002 A YU P20050002A RS 20050002 A RS20050002 A RS 20050002A
- Authority
- RS
- Serbia
- Prior art keywords
- antidiabetic
- substituted heterocyclic
- bond
- antiobesity agents
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Supstituisani heterociklični derivati koji se koriste kao antidijabetski i agensi protiv gojaznosti i metod. Data su jedinjenja koja su korisna kao antidijabetski agensi i agensi protiv gojaznosti i imaju strukturu (I) gde m je 0,1 ili 2; n je 0,1 ili 2; Q je C ili N; A je (CH2)x gde x je od 1 do 5, ili A je (CH2)x gde x 1 je od 1 do 5 sa jednom alkenil vezom ili alkinil vezom ugrađenom bilo gde u lancu, ili A je –(CH2)x2-O- (CH2)x3 – gde x2 je od 1 do 5 i x3 je od 0 do 5, ukoliko je bar jedan od x2 i x3 različit od 0; B je veza ili je (CH2)x 4 gde x4 je od 1 do 5; X je CH ili N; X2 je C, N, O ili S; X3 je C, N, O ili S; X4 je C, N, O ili S; X5 je C, N, O ili S; X6 je C, N, O ili S; ukoliko je bar jedan od X2, X3, X4, X5 i X6 je N; i bar jedan od X2, X3, X4, X5 i X6 je C, i posebno isključujući strukturu (II) gde X2=N, X3=C, X4=O ili S, Z=0 ili veza; R1 je H ili alkil; R2 je H, alkil, alkoksi, halogen, amino ili supstituisani amino ili cijano grupa; R2a, R2b i R2c mogu biti isti ili različiti i izabrani su između H, alkil, alkoksi, halogen, amino ili supstituisani amino ili cijano grupe; a R3 i Y, koji su ovde definisani, i čija jedinjenja su korisna u lečenju dijabetesa i gojaznosti.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39455302P | 2002-07-09 | 2002-07-09 | |
| PCT/US2003/021331 WO2004004655A2 (en) | 2002-07-09 | 2003-07-08 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS20050002A true RS20050002A (en) | 2007-09-21 |
Family
ID=30115733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YUP-2005/0002A RS20050002A (en) | 2002-07-09 | 2003-07-08 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6875782B2 (sr) |
| EP (1) | EP1531810B1 (sr) |
| JP (1) | JP4541883B2 (sr) |
| KR (1) | KR101120337B1 (sr) |
| CN (1) | CN1665500A (sr) |
| AT (1) | ATE543497T1 (sr) |
| AU (1) | AU2003248861B2 (sr) |
| BR (1) | BR0312503A (sr) |
| CA (1) | CA2490972C (sr) |
| ES (1) | ES2380319T3 (sr) |
| GE (1) | GEP20084475B (sr) |
| HR (1) | HRP20050001A2 (sr) |
| IL (1) | IL165809A (sr) |
| IS (1) | IS7629A (sr) |
| MX (1) | MXPA05000279A (sr) |
| NO (1) | NO329328B1 (sr) |
| NZ (1) | NZ537251A (sr) |
| PL (1) | PL375230A1 (sr) |
| RS (1) | RS20050002A (sr) |
| RU (1) | RU2325381C2 (sr) |
| UA (1) | UA79296C2 (sr) |
| WO (1) | WO2004004655A2 (sr) |
| ZA (1) | ZA200500029B (sr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0312929A (pt) * | 2002-08-01 | 2005-07-12 | Neurosearch As | Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo |
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| US20060183897A1 (en) * | 2003-03-18 | 2006-08-17 | Chakravarty Prasun K | Biaryl substituted triazoles as sodium channel blockers |
| FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861300B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861301B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR2861302A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| WO2005051298A2 (en) * | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| CA2558766A1 (en) | 2004-03-05 | 2005-09-22 | The Trustees Of The University Of Pennsylvania | The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
| WO2005115384A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
| JP2008500357A (ja) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Ｐｐａｒのモジュレーターとしての置換されたトリアゾールおよびこれらの調製方法 |
| WO2006032042A2 (en) * | 2004-09-15 | 2006-03-23 | Regeneron Pharmaceuticals, Inc. | Us of cntf or a cntf derivative in combination with a further compound for the preparation of medicament for the treatment of obesity |
| WO2006039334A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
| WO2006105127A2 (en) | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| WO2006117743A1 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Substituted aromatic compounds as antidiabetic agents |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| JP2008545711A (ja) * | 2005-05-26 | 2008-12-18 | メタバシス・セラピューティクス・インコーポレイテッド | 新規ホスフィン酸含有甲状腺ホルモン様剤 |
| FR2889191A1 (fr) * | 2005-07-28 | 2007-02-02 | Cerep Sa | Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1 |
| EP1942898B2 (en) | 2005-09-14 | 2014-05-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
| JP5122462B2 (ja) | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| EP1948163A2 (en) * | 2005-10-18 | 2008-07-30 | Aegerion Pharmaceuticals | Methods for treating disorders associated with hyperlipidemia in a mammal |
| BRPI0712802A2 (pt) * | 2006-05-30 | 2012-10-23 | Astrazeneca Ab | composto, métodos para produzir uma inibição da atividade de dgat1, e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para preparar um composto |
| WO2007138304A1 (en) * | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
| US20080009534A1 (en) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US20080161279A1 (en) * | 2006-12-21 | 2008-07-03 | Wisler Gerald L | Methods of Treating Obesity |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN103694195B (zh) * | 2013-09-18 | 2016-04-06 | 华东师范大学 | 芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途 |
| EP3190103A1 (en) * | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
| EP3634426A4 (en) | 2017-06-05 | 2021-04-07 | Viking Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS |
| KR101943382B1 (ko) | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3290664B2 (ja) | 1993-12-28 | 2002-06-10 | 明治製菓株式会社 | ３環性ベンゾアゼピンおよびベンゾチアゼピン誘導体 |
| EP0760658B1 (en) * | 1994-05-27 | 2002-11-13 | Merck & Co. Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
| WO1997000258A1 (fr) | 1995-06-15 | 1997-01-03 | Meiji Seika Kabushiki Kaisha | Composes de benzazepine tricyclique |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| JP3215048B2 (ja) * | 1996-04-03 | 2001-10-02 | 日本たばこ産業株式会社 | プロピオン酸誘導体及びその用途 |
| JPH1067759A (ja) | 1996-06-20 | 1998-03-10 | Sankyo Co Ltd | 除草性アゾール誘導体 |
| JPH11263775A (ja) | 1997-09-08 | 1999-09-28 | Sankyo Co Ltd | ヒドロキシアニリン誘導体 |
| TW510902B (en) | 1997-09-29 | 2002-11-21 | Meiji Seika Kaisha | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents |
| DE69941777D1 (de) * | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| FR2778314B1 (fr) | 1998-05-07 | 2002-06-14 | Rhone Poulenc Agrochimie | Composition fongicide synergique comprenant un compose analogue de la strobilurine |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| WO2001017994A1 (en) | 1999-09-08 | 2001-03-15 | Glaxo Group Limited | Oxazole ppar antagonists |
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| TWI260321B (en) * | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| DK1228067T3 (da) | 1999-11-10 | 2004-12-06 | Takeda Chemical Industries Ltd | 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning |
| GB0029974D0 (en) * | 2000-12-08 | 2001-01-24 | Glaxo Group Ltd | Chemical compounds |
-
2003
- 2003-07-08 MX MXPA05000279A patent/MXPA05000279A/es active IP Right Grant
- 2003-07-08 JP JP2004520018A patent/JP4541883B2/ja not_active Expired - Fee Related
- 2003-07-08 RS YUP-2005/0002A patent/RS20050002A/sr unknown
- 2003-07-08 US US10/616,283 patent/US6875782B2/en not_active Expired - Lifetime
- 2003-07-08 NZ NZ537251A patent/NZ537251A/en not_active IP Right Cessation
- 2003-07-08 BR BRPI0312503-3A patent/BR0312503A/pt not_active IP Right Cessation
- 2003-07-08 KR KR1020057000362A patent/KR101120337B1/ko not_active IP Right Cessation
- 2003-07-08 AT AT03763345T patent/ATE543497T1/de active
- 2003-07-08 ES ES03763345T patent/ES2380319T3/es not_active Expired - Lifetime
- 2003-07-08 RU RU2005103395/04A patent/RU2325381C2/ru not_active IP Right Cessation
- 2003-07-08 CA CA2490972A patent/CA2490972C/en not_active Expired - Fee Related
- 2003-07-08 GE GEAP8617A patent/GEP20084475B/en unknown
- 2003-07-08 EP EP03763345A patent/EP1531810B1/en not_active Expired - Lifetime
- 2003-07-08 AU AU2003248861A patent/AU2003248861B2/en not_active Ceased
- 2003-07-08 WO PCT/US2003/021331 patent/WO2004004655A2/en active Application Filing
- 2003-07-08 PL PL03375230A patent/PL375230A1/xx not_active Application Discontinuation
- 2003-07-08 CN CN038160382A patent/CN1665500A/zh active Pending
- 2003-08-07 UA UAA200501187A patent/UA79296C2/uk unknown
-
2004
- 2004-12-16 IL IL165809A patent/IL165809A/en not_active IP Right Cessation
- 2004-12-17 NO NO20045529A patent/NO329328B1/no not_active IP Right Cessation
- 2004-12-17 US US11/016,183 patent/US7507757B2/en active Active
-
2005
- 2005-01-03 ZA ZA200500029A patent/ZA200500029B/xx unknown
- 2005-01-04 HR HR20050001A patent/HRP20050001A2/hr not_active Application Discontinuation
- 2005-01-05 IS IS7629A patent/IS7629A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS20050002A (en) | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | |
| WO2004004665A3 (en) | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | |
| RS93604A (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| WO2004043367A3 (en) | Fused heterocyclic compounds and use thereof | |
| GEP20074019B (en) | Heterocyclic aromatic compounds useful as growth hormone secretagogues | |
| GB0318343D0 (en) | No title | |
| AU2003293529A8 (en) | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use | |
| MY136764A (en) | Indole-3-carboxamides as glucokinase (gk) activators | |
| GB0318438D0 (en) | Early entry | |
| DE60316842D1 (de) | Fluorierte polyetherzusammensetzungen | |
| HK1096549A1 (en) | Imidazopyridine-derivatives as inducible no-synthase inhibitors | |
| AP2002002578A0 (en) | Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses. | |
| PH12015501098A1 (en) | Antituberculous composition comprising oxazole compounds | |
| CO5580821A2 (es) | 4-cetolactamas y -lactonas 3-fenil-3-substituidas, espirociclicas | |
| TW200505337A (en) | Substituted benzoyl derivatives as herbicides | |
| HK1096548A1 (en) | Imidazopyridine-derivatives as inductible no-synthase inhibitors | |
| TW200609228A (en) | Substituted n-acyl-2-aminothiazoles | |
| MXPA06003345A (es) | Derivados de aminopiridina como inhibidores de la no-sintasa inducible. | |
| ATE460938T1 (de) | Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion | |
| MXPA04006920A (es) | Compuestos para modular la proliferacion celular. | |
| ITMI20020624A1 (it) | Composizioni ad attivita' biostimolante | |
| PL372930A1 (en) | N-{[(2s)-4- (3,4-difluorobenzyl) morpholin-2yl] methyl} -2-{3-[(methylsulphonyl) amino] phenyl} acetamide as ccr3 antagonist for the treatment of inflammatory conditions | |
| CO5680398A2 (es) | Derivados heterociclicos sustituidos utiles como agentes an- tidiabeticos y antiobesidad y metodo | |
| ATE340175T1 (de) | Imidazo(4,5-böchinolinderivate und ihre verwendung als inhibitoren der induzierbaren no- synthase | |
| TW200628459A (en) | Enantiopure heterocyclic compound |